Phase II Study of Ablation Combined With PD-1 Antibody in Patients With Hepatocellular Carcinoma
Overview
- Phase
- Phase 1
- Intervention
- PD-1 monoclonal antibody
- Conditions
- Hepatocellular Carcinoma
- Sponsor
- Sun Yat-sen University
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Measure Tolerability
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC), with the secondary study objective to preliminarily evaluate the efficacy of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with HCC and the exploratory study objective to evaluate the effect of ablation combined with PD-1 monoclonal antibody on immune function and hepatitis virus infection status in patients with HCC. This study will be divided into two stages, and the first stage is to enroll 6 patients for dose-limited toxicity (DLT) observation. If DLT appeared in < 2 patients, the second stage was entered and the other 24 patients were further enrolled.
Detailed Description
The enrolled patients received intravenous injection of PD-1 monoclonal antibody (tirelizumab 200mg) on the day before ablation and the 21 (± 7) days, the 42 (+ 7) days and the 63 (+ 7) days after ablation, respectively (a total of 4 times). Liver tumor biopsy was performed during ablation, tissue samples will be stored for pathological examination and test of PD-L1 expression. Liver enhanced MRI or CT and contrast-enhanced ultrasound were reviewed within 4 \~ 6 weeks after the first ablation treatment to evaluate the complete response rate of the tumor after treatment. Patients suspected of local incomplete ablation in either of the two examinations could receive a salvage ablation for once within 12 weeks of the first ablation, but no extra dose of PD-1 antibody would be given. Patients with residual viable tumor after re-ablation were defined as treatment failure. The first six patients (stage I) underwent detailed physical examination on the 2nd, 7th, 14th and 21st days after receiving the first dose of study drug, and 30 days after the 2nd and 4th doses of study drugs. Blood tests and urine routine were performed on the 2nd day after treatment, as well as ECG examination. In the second stage, the patients underwent examinations on the second and 21st days after the dose of study drug, and on the 30 days after the last dose of study drug (the above examination can be carried out within ± 7 days). If there are clinically significant study related adverse events (including abnormal test results) in patients in stage I, necessary reexamination and visit would be added in patients in stage II. Radiological evaluation arrangement: liver enhanced MRI or CT and contrast-enhanced ultrasound were performed within 4 \~ 6 weeks after the first ablation. The second imaging examination would be completed within 4 \~ 6 weeks after the end of the study treatment, and then examined according to the following schedule: CT / MRI was repeated every 3 months within the first year, then every 4 months within the next year, and every 6 months after 2 years. The investigators will evaluate the adverse events during the follow-up. After the patients have radiologically confirmed recurrence and/or metastasis, they will be treated according to the guideline without limitation. The information of all anti-cancer treatments they received need to be collected. Follow-up by phone will be conducted at least every 6 months until death to find out the patient's survival data, as well as their physical condition and information about other anticancer treatment received.
Investigators
Chen Min-Shan
Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •Patients who voluntarily participate in the study and sign the informed consent form
- •18 \~ 75 years old, both men and women
- •Clinical diagnosis of hepatocellular carcinoma, conforming to the indications of radiofrequency or microwave ablation
- •Child-Pugh score ≤6 (Child-Pugh score A)
- •Barcelona Clinic Liver Cancer (BCLC) Stage A or B
- •Number of tumors ≤ 2; 2 cm\<maximum diameter≤ 5 cm
- •No distant metastasis or lymph node metastasis (defined as lymph node maximum transverse diameter ≥ 15 mm)
- •ECOG score 0 or 1
- •No history of drug allergy;
- •The function of vital organs meets the following requirements (no blood component, cell growth factor and other corrective treatment drugs are allowed to be used 14 days before enrollment) 1）Absolute neutrophil count≥1.5×109/L; 2）Platelets≥80×109/L; 3）Hemoglobin≥90 g/L; 4）Serum albumin≥30 g/L; 5）Thyroid stimulating hormone (TSH) ≤1×ULN (if abnormal, FT3 and FT4 should also be investigated, and patients whose FT3 and FT4 levels are normal can be enrolled); 6) Bilirubin≤1.5×ULN (within 7 days prior to the first dose); 7) ALT and AST≤3×ULN (within 7 days prior to the first dose); 8) No prolongation of PT by more than 3 seconds above the ULN; 9)Serum creatinine≤1.5×ULN;
Exclusion Criteria
- •Patients unsuitable for percutaneous radiofrequency or microwave ablation for any reason
- •Any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; vitiligo; patients with complete remission of asthma in childhood but requiring no intervention after adulthood can be included; patients with asthma requiring medical intervention with bronchodilators can not be included)
- •Patients who need to use immunosuppressive agents or require systemic hormone therapy to achieve the purpose of immunosuppression (dose \> 10 mg/day prednisone or other effective hormones) and are still using them within 2 weeks before enrollment
- •Prior systemic anticancer therapy
- •Received or intended to receive other anticancer therapy (vascular intervention, etc.) other than surgical resection or ablative therapy
- •Known history of central nervous system metastasis or hepatic encephalopathy
- •Tumor necrosis cannot be confirmed by reexamination of imaging after local ablation
- •Clinically symptomatic ascites requiring puncture and drainage or those who have received ascites drainage in the past 3 months, except those with only a small amount of ascites shown by imaging but not accompanied by clinical symptoms
- •Hypertension not well controlled by antihypertensive medication (systolic blood pressure≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg)
- •Uncontrolled cardiac clinical symptoms or diseases, such as: (1) heart failure above NYHA2; (2) unstable angina; (3) myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention; (5)QTc \> 450 ms (male); QTc \> 470 ms (female)
Arms & Interventions
Radiofrequency or microwave ablation combined with PD-1 monoclonal antibody
Patients who meet the inclusion criteria will receive 1 cycle of PD-1 antibody on the day before ablation, then 3 cycles of PD-1 antibody after primary radiofrequency or microwave ablation, on a schedule of per 3 weeks, then be followed until disease relapse or death.
Intervention: PD-1 monoclonal antibody
Radiofrequency or microwave ablation combined with PD-1 monoclonal antibody
Patients who meet the inclusion criteria will receive 1 cycle of PD-1 antibody on the day before ablation, then 3 cycles of PD-1 antibody after primary radiofrequency or microwave ablation, on a schedule of per 3 weeks, then be followed until disease relapse or death.
Intervention: Radiofequencey or microwave ablation
Outcomes
Primary Outcomes
Measure Tolerability
Time Frame: from the start of PD-1 monoclonal antibody therapy to 90 days after treatment
Measured as the rate of patients able to complete treatment as planned in the study.
Measure Safety
Time Frame: from the start of PD-1 monoclonal antibody therapy to 90 days after treatment
Treatment-related adverse events (TRAEs) and serious adverse events (SAEs) occurring from the start of PD-1 monoclonal antibody therapy to 90 days after treatment were observed and judged according to CTCAE 5.0 criteria.
Secondary Outcomes
- Local Recurrence Rate (LRR) and Distant Metastasis Rate (DMR)(Two years)
- Median Disease-free survival (mDFS)(Two years)
- 1- and 2-year disease-free survival (DFS) and overall survival (OS) rates(Two years)
- Complete Response (CR1)(Two years)
- Treatment Failure Rate (TFR)(Two years)